Vincerx Pharma, Inc. (VINC): Price and Financial Metrics
GET POWR RATINGS... FREE!
VINC Stock Price Chart Interactive Chart >
VINC Price/Volume Stats
|Current price||$1.64||52-week high||$18.43|
|Prev. close||$1.61||52-week low||$1.40|
|Day high||$1.67||Avg. volume||108,276|
|50-day MA||$2.91||Dividend yield||N/A|
|200-day MA||$9.00||Market Cap||34.54M|
Vincerx Pharma, Inc. (VINC) Company Bio
Vincerx Pharma, Inc. operates as a clinical-stage life sciences company. The Company focuses on developing VIP152 inhibits PTEFb phosphorylation of RNA polymerase II (RNAPII), thereby preventing transcription elongation and blocking expression of genes that drive cancer. Vincerx Pharma serves customers worldwide.
Most Popular Stories View All
VINC Latest News Stream
|Loading, please wait...|
VINC Latest Social Stream
View Full VINC Social Stream
Latest VINC News From Around the Web
Below are the latest news stories about Vincerx Pharma Inc that investors may wish to consider to help them evaluate VINC as an investment opportunity.
PALO ALTO, Calif., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced that Vincerx’s management team will participate in a fireside chat and one-on-one investor meetings at the SVB Leerink 11 th Annual Global Healthcare Conference, to be held virtually February 14-18, 2022.
In a report released today, Michael King from H.C. Wainwright reiterated a Buy rating on Vincera Pharma (VINC – Research Report), with a price target of $25.00. The company's shares closed last Thursday at $7.21, close to its 52-week low of $6.23. According to TipRanks.com, King is a 4-star analyst with an average return of 12.4% and a 43.9% success rate. King covers the Healthcare sector, focusing on stocks such as Sonnet BioTherapeutics Holdings, Intellia Therapeutics, and Werewolf Therapeutics. Currently, the analyst consensus on Vincera Pharma is a Strong Buy with an average price target of $25.50.
Vincerx Pharma Publishes Preclinical Data Demonstrating Therapeutic Potential of Small Molecule-Drug Conjugate VIP236 in the Journal Cancers
VIP236 is a first-in-class anticancer agent, optimized using Vincerx’s proprietary modular bioconjugation platform to target aggressive tumors VIP236 demonstrates promising tumor regression in in vivo cancer models and is currently in IND-enabling studies PALO ALTO, Calif., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced th
Small-capitalization stocks have been hit particularly hard over the past months. A look at the Russell 2000, the leading index of small caps, tells the story. The Russell last hit a record high back in November of last year, and it's gone mostly downhill from there -- falling 20%. But low prices now could translate into investor opportunities later on. In fact, Jefferies strategist Steven DeSanctis believes that the small caps are in a "bottoming out process." DeSanctis argues that “valuations
It is usually uneventful when a single insider buys stock. However, When quite a few insiders buy shares, as it...
VINC Price Returns